Annotation Detail

Information
Associated Genes
AREG
Associated Variants
AREG EXPRESSION
AREG EXPRESSION
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as "high expressor" (either EREG or AREG mRNA level) or "low expressor" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P < .001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P = .73; interaction test results were significant [P = .01]). Results were less clear for response rate (interaction P = .17) and OS (interaction P = .11).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1020
Gene URL
https://civic.genome.wustl.edu/links/genes/389
Variant URL
https://civic.genome.wustl.edu/links/variants/315
Rating
4
Evidence Type
Predictive
Disease
Colorectal Cancer
Evidence Direction
Supports
Drug
Panitumumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26867820
Drugs
Drug NameSensitivitySupported
PanitumumabSensitivitytrue